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Cardiovascular Depression and Stabilization
by Central Vasopressin in Rats
Yutaka Imai, Keishi Abe, Shuichi Sasaki, Naoyoshi Minami,
Masanori Munakata, Hiromichi Sakuma, Junichiro Hashimoto, Toshima Nobunaga,
Hiroshi Sekino, and Kaoru Yoshinaga
The role of endogenous vasopressin in cardiovascular homeostasis was examined using
vasopressin-deftcient rats (Brattleboro) (n=194) and their parent strain, Long-Evans rats
(n=181). Mean arterial pressure (blood pressure) and heart rate were measured every 4
seconds with or without infusion of drug solution for 21 hours, and mean values and their
standard deviations (lability) were calculated. Blood pressure in Brattleboro rats (116±1.1
mm Hg, mean±SEM) was significantly higher than that in Long-Evans rats (96±0.7 mm Hg,
/><0.001), whereas heart rates (381±33 and 375±2.9 beats/min, respectively) were similar. The
lability of blood pressure and heart rate in Brattleboro rats (9.2±0.1 mm Hg and 42 J±0.7
beats/min) was also greater than that in Long-Evans rats (6.7 ±0.1 mm Hg, p< 0.001 and
38.4±0.8 beats/min, p<0.0l, respectively). In Brattleboro rats, intravenous vasopressin (0.1
ng/kg/min or 0.6 ng/kg/min) did not affect blood pressure, although it did reduce heart rate
and decreased lability of blood pressure and heart rate. Intracerebroventricular (central)
infusion of vasopressin (2 pg/kg/min) in Brattleboro rats induced initial hypertension and
tachycardia followed by long-lasting hypotension and bradycardia, whereas in Long-Evans rats
it induced only hypertension and tachycardia. In both strains, central vasopressin dramatically
decreased the lability of blood pressure and heart rate. Neither intravenous (0.2 ng/kg/min)
nor central desmopressin (2 pg/kg/min or 0.2 ng/kg/min), a V2 renal receptor agonist, changed
any of these parameters in Brattleboro rats, although both diminished urinary volume. Neither
intravenous (50 ng/kg/min) nor central (3.3 pg/kg/min) <f(CH2)5-Tyr(Me)-arginine vasopres-
sin, a vasopressin V, receptor antagonist, modulated any of these parameters in Long-Evans
rats. These results suggest that endogenous as well as exogenous vasopressin acts centrally as
a cardiovascular inhibitor and stabilizer through a receptor mechanism other than V, or V3
receptor mechanisms. (Hypertension 1990;15:291-300)
Arginine vasopressin (AVP) has long beenknown to possess potent vasoconstrictorproperties.1 However, when AVP is infused
intravenously into conscious animals or humans,
there is no increase in blood pressure until extremely
high plasma AVP levels are achieved.2 Evidence has
accumulated indicating that the absence of increases
in blood pressure in response to AVP infusion in
normotensive animals may be due to the presence of
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an effective and specific buffering system.3-5 On the
basis of available evidence, it has been proposed that
the locus of this buffering system is in the central
nervous system.6-12 Recently, it has been reported
that Brattleboro rats with hereditary hypothalamic
diabetes insipidus (DI rats) have suppressed barore-
ceptor reflex sensitivity.9 Exogenous AVP and the V2
renal receptor agonist desmopressin (DDAVP)
administered systemically is able to restore this sup-
pressed sensitivity to within the range that is normal
for Long-Evans (LE) rats.9 It is believed that the
inhibition of baroreceptor reflex pathway raises
blood pressure.13 Therefore, it may be postulated
that rats with suppressed baroreceptor reflex mech-
anisms will have higher blood pressure and heart rate
and a greater lability of blood pressure and heart rate
than normal rats. Furthermore, we previously
reported that centrally administered AVP lowered
blood pressure in DI rats as well as in stroke-prone
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spontaneously hypertensive rats (SHR), whereas it
elevated blood pressure in normal LE rats and
Wistar-Kyoto (WKY) rats.14-15 This line of evidence
encouraged us to examine the difference in blood
pressure and heart rate characteristics between DI
and LE rats; in the former, AVP was lacking in the
central nervous system as well as in the peripheral
circulation. In the present study, we examined the
effect of a small amount of AVP or vasopressin
analogues intravenously or intracerebroventricularry
infused over 21 hours on blood pressure, heart rate,
and lability of blood pressure and heart rate in DI rats
as well as in LE rats. To analyze the characteristics
and responses of blood pressure and heart rate accu-
rately, we used continuous blood pressure and heart
rate monitoring systems in conscious, unrestrained
rats and analyzed the data with a microcomputer.
Methods
Animals
DI rats and their parent strain, LE rats, weighing
150-400 g and 15-45 weeks of age, were used. These
rats were divided into groups matched by age: 15-
19-week-old group, LE rats 18.1±0.6 weeks, 275±13
g, mean±SD, n=33 and DI rats 18.0+0.5 weeks,
252 ±14 g, «=32; 20-24 -week-old group, LE rats
22.9±0.5 weeks, 298±9 g, n=A5, DI rats 23.5±0.4
weeks, 270+13 g, n=40; 25-29-week-old group, LE
rats 27.6±03 weeks, 348±18 g, n=34, DI rats 27.3±0.3
weeks, 312±15 g, n=32; 30-35-week-old group, LE
rats 33.0±0.4 weeks, 369±10 g, n=35, DI rats 32.0±0.5
weeks, 340±13 g, n=55; and 35-week-old group, LE
rats 39.6±1.4 weeks, 378±14 g, n=2A, DI rats 40.1 ±0.8
weeks, 348±19 g, n=35. The rats were placed into
individual plastic metabolic cages and housed under
conditions of constant temperature (23±1°C) and
humidity (60%), with a 12-hour light/dark cycle. The
rats were housed in an isolated room, but the room was
not soundproof. The rats were continuously exposed to
the noise from infusion pumps and neighboring rats.
The environmental conditions were common for all
experiments. The rats were fed a commercial diet and
water ad libitum.
Surgical Procedure and Measurement of Arterial
Pressure and Heart Rate
While the rats were under ether anesthesia, the
left femoral artery and vein were cannulated with
polyethylene tubing. The tip of the arterial catheter
(Intramedic PE-100; Gay Adams, Parsippany, New
Jersey) was tapered by heating for insertion into the
femoral artery. In some rats, venous catheters (Intra-
medic PE-20) were implanted bilaterally. The cathe-
ters were passed subcutaneously and brought out on
the neck. During surgery, 15 mg aminobenzyl peni-
cillin was administered topically and intraperitone-
ally. The arterial catheter was connected to a hydrau-
lic swivel-tethering system. Rats were allowed to
recover for at least 24 hours after surgery and were
conscious and unrestrained during the subsequent
studies. Blood pressure was recorded from the fem-
oral artery catheter with a P23ID Statham pressure
transducer (Oxnard, California) and strain-gauge
amplifier (model 1257, NEC-San-ei, Tokyo, Japan).
To keep the arterial catheter patent, heparin physi-
ological saline solution (100 units/ml) was infused
continuously at a rate of 80 /il/hr. Heart rate was
counted from the phasic pressure pulse by a cardio-
tachometer (model 1321, NEC-San-ei). The analog
signals of phasic pressure, mean arterial pressure,
and heart rate were fed into an analog/digital (A/D)
converter (Mark-1, N.C.C., Tokyo, Japan). Digital
signals of mean arterial pressure and heart rate from
the A/D converter were fed into a microcomputer
(HP-9816, Hewlett-Packard, Fort Collins, Colorado)
at 4-second intervals over a period of 21 hours. The
recording was started at any time between 9:00 AM
and 6:00 PM. At the end of the measurement period,
the processed data was printed (Hewlett-Packard
82906A). Mean values and standard deviation for
every hour, time trend-gram, mean values and stan-
dard deviation for 21 hours, and percent frequency
histograms for each parameter were put out. Mean
values and standard deviations of blood pressure and
heart rate for every hour and for 21 hours were
calculated by using all data sampled at 4-second
intervals for each period. The lability of mean arte-
rial pressure and heart rate was expressed as stan-
dard deviation of each parameter averaged over 21
hours or every hour. Analog data was monitored
simultaneously with a recticorder (Rectigraph 8K,
NEC-San-ei). While under pentobarbital anesthesia
(40 mg/kg i.p., Nembutal, Abbott, North Chicago,
Illinois), the lateral cerebroventricle in some LE and
DI rats was cannulated (Intramedic PE-20, 4.6 cm in
length with approximate capacity of 4.6 /A). Coordi-
nates for the cannulation with respect to the bregma
were 1.0 mm posterior, 1.5 mm lateral, and 5.0 mm
deep. The cannulae were filled with artificial cere-
brospinal fluid (ACSF) (mmol/1) (sodium 148.4,
potassium 3.0, magnesium 1.0, calcium 2.5, HPO41.5,
chloride 156.9, glucose 3) and fixed in place with
stainless steel anchoring screws and orthopedic bone
cement. A week after the cerebroventricular cannu-
lation, the femoral artery and vein were cannulated.
Experimental Protocol
In the following study 25-29-week-old rats were
used. In all experiments, a time control base was
obtained with either intracerebroventricular ACSF
infusion at a rate of 4.6 .^1/hr or intravenous infusion
of physiological saline solution at a rate of 40 jtl/hr.
Intravenous infusion studies. Mean arterial pressure
and heart rate in DI rats were measured with and
without intravenous infusion of either AVP (Protein
Research Foundation, Osaka, Japan) (at a rate of 2
pg/kg/min for 21 hours [«=7], 0.1 ng/kg/min for 21
hours [n=8], or 0.6 ng/kg/min for 21 hours [n=7]) or
l-(3-mercaptopropionic acid)-8-D-AVP (desmo-
pressin) (DDAVP, Ferring, Malmo, Sweden), a V2
renal receptor agonist (0.2 ng/kg/min for 21 hours
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[n=7]). In LE rats, mean arterial pressure and heart
rate were measured with and without intravenous
infusion of l-0-mercapto-/3,/3-cyclopentamethylene-
propionicacid),2-(O-methyl) tyrosine-AVP, [d(CH2)5-
Tyr(Me)]-AVP (Peninsula, San Carlos, California16),
a V, vascular receptor antagonist (AVP antagonist) at
a rate of 50 ng/kg/min for 21 hours (n=T).
Intracerebroventricular infusion studies. In 21 DI
rats, blood pressure and heart rate were measured
for 21 hours during intracerebroventricular infusion
of ACSF on the third and fourth day after surgery,
and the reproducibility of blood pressure, heart rate,
and their lability were evaluated.
AVP (2 pg/kg/min in eight LE rats and 13 DI rats),
desmopressin (2 pg/kg/min and 0.2 ng/kg/min in each
of six DI rats), or AVP antagonist (3.3 pg/kg/min in
eight LE rats) was infused intracerebroventricularly
for 21 hours, and blood pressure and heart rate (mean
and standard deviation) were examined.
All stock solutions (dissolved in 0.1/V acetic acid)
were diluted with 0.9% saline or ACSF to the desired
concentrations. The venous and cerebroventricular
catheters were connected to PE-20 tubing, which was
attached to a Princeton infusion pump (model 575,
Natick, Massachusetts). Drug solutions were infused
intravenously at a rate of 40 .^1/hr and intracerebro-
ventricularly at a rate of 4.6 fil/hi. Intravenous and
central drug infusion lasted 21 hours, the initial hour
of which was required to clear the dead space of the
venous or cerebroventricular cannula. The data of
the initial hour of intracerebroventricular drug infu-
sion were estimated as the control for time sequence
analysis and expressed as preinfusion period in the
figure (0 hour). In all experiments, 21-hour urine
samples were collected.
Statistical Analysis
All values were expressed as mean±SEM unless
otherwise stated. Statistical tests included one-way
analysis of variance (ANOVA), two-way ANOVA for
repeated measurements, and Duncan's multiple
range test where appropriate.
Results
Blood Pressure, Heart Rate, and Their Lability in
Long-Evans and Diabetes Insipidus Rats
The mean arterial pressure and its standard devi-
ation (lability) in DI rats averaged for the 21-hour
study period (116±1.1 mm Hg and 9.2±0.1 mm Hg,
respectively, «=194) were significantly higher than
those in LE rats (96+0.7 mm Hg, F=21.3 and
6.7±0.1 mmHg, F=13.9, respectively, n = 181,
/?<0.001). The lability of heart rate, averaged for the
21-hour study period in DI rats (42.3 ±0.7 beats/min),
was also greater than that in LE rats (38.4 ±0.8
beats/min, F=7.2, p<0.0l); the heart rate averaged
for the 21-hour study period in DI rats (381 ±3.3
beats/min) was similar to that in LE rats (375 ±2.9
beats/min, F=3J,p>0.05). Figure 1 presents typical
records of mean arterial pressure for the 21-hour
study period in LE and DI rats, respectively. Figure 2
demonstrates the relation between age (weeks) and
each parameter. The mean arterial pressure and its
standard deviation, averaged for the 21-hour study
period in DI rats, were significantly higher than those
in LE rats of each age group. The heart rate,
however, was similar in both groups of rats at all ages.
The standard deviation of the heart rate, averaged
for the 21-hour study period in DI rats younger than
30 weeks, was higher than that in LE rats of the same
age. This difference was not evident in rats over 30
weeks of age. The lability of blood pressure and heart
rate in DI rats as demonstrated by variation coeffi-
cient was still significantly higher in DI rats than that
in LE rats (Table 1).
In the following experiments, 25-29-week-old rats
were used. Table 2 shows basal values and standard
deviations of blood pressure and heart rate averaged
for 1 hour in the control period (0 hour).
Effects of Intravenously Administered Arginine
Vasopressin, Desmopressin, or Arginine Vasopressin
Antagonist on Blood Pressure, Heart Rate,
and Their Lability
Figure 3A demonstrates the effect of intravenous
AVP (0.6 ng/kg/min for 21 hours) in DI rats (n=7)
on each variable. AVP did not affect the mean
arterial pressure averaged for the 21-hour study
period (0.1 ng/kg/min: 117±0.8 vs. 115±0.9 mm Hg;
0.6 ng/kg/min: 106+1.0 vs. 107±2.3 mmHg);
whereas it did induce a significant bradycardia (0.1
ng/kg/min: 372±9.5 vs. 360±3.9 beats/min; 0.6 ng/
kg/min: 369±8.7 vs. 349±4.9 beats/min, p<0.01,
respectively) and did decrease the standard devia-
tions of mean arterial pressure (0.1 ng/kg/min:
9.2±0.7 vs. 7.2±0.3 mm Hg; 0.6 ng/kg/min: 8.5±0.5
vs. 6.9±0.4 mmHg,p<0.01, respectively) and heart
rate (0.1 ng/kg/min: 43.3±1.9vs. 39.6± 1.2beats/min;
0.6 ng/kg/min: 44.1+2.1 vs. 38.0±2.6 beats/min,
p<0.01, respectively) averaged for the 21-hour study
period, suggesting the stabilization of mean arterial
pressure as well as heart rate. Figure 4 represents the
results of time-sequence analysis of blood pressure,
heart rate, and their lability (standard deviations)
with and without intravenous infusion of AVP at a
rate of 0.6 ng/kg/min. It is apparent that heart rate
(two-way ANOVA, Flr272=36.1,/?<0.0001) and labil-
ity of mean arterial pressure i7lj272=38.1, /?<0.0001)
and heart rate (F1JT2=21.2, p<0.0001) dramatically
decreased immediately after the start of infusion.
These doses of AVP significantly decreased the 21-
hour urinary volume (0.1 ng/kg/min: 303±52 to
175±12 ml; 0.6 ng/kg/min: 263±31 to 119+9 ml,
/><0.001, respectively), although this was still above
the normal range in LE rats. AVP infused intrave-
nously at a rate of 2 pg/kg/min did not affect blood
pressure, heart rate, or their lability.
Figure 3B illustrates the effect of intravenous desmo-
pressin (0.2 ng/kg/min for 21 hours) in DI rats (n=7)
on each variable. This dose reduced the production of
urine from 339±42 to 18±3 ml/21 hours. However,
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FIGURE 1. Upper panels present a typical recording of the time trend of mean arterial pressure
(MAP) over 21-hour study period in Long-Evans (LE) rat (left side panel) and in Brattleboro (DI)
rat (right side panel). Each point represents mean ±SD of measurements over each 10-minute period.
Bottom panels present percent frequency histogram of MAP values over 21-hour period.
desmopressin did not affect mean arterial pressure
(127±2.6 vs. 131 ±2.8 mm Hg), heart rate (364± 10.6 vs.
361 ±14.6 beats/min), and the standard deviations of
mean arterial pressure (10.3±0.6 vs. 10.9±0.8 mm Hg)
and heart rate (42.1 ±2.6 vs. 39.6±13 beats/min) aver-
aged for the 21-hour study period.
As shown in Figure 3C, intravenous AVP antago-
nist (50 ng/kg/min for 21 hours) did not cause any
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FIGURE 2. Line graphs showing mean arte-
rial pressure (MAP), heart rate (HR), and
standard deviations (SD) of MAP and HR
(lability) averaged for 21-hour period in Long-
Evans (LE) (o) and Brattleboro (•) rats of
various ages. **p<0.01; ***p<0.001 com-
pared with normal LE rats. ip<0.05;
flp<0.0i; tttp<0-00^ compared with 15-19-
week-old rats (Duncan's multiple range test).
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 at TOHOKU UNIVERSITY on September 15, 2011http://hyper.ahajournals.org/Downloaded from 
lmai et al Cardiovascular Effect of Vasopressin 295
TABLE 1. Variation Coefficient of Mean Arterial Pressure and Heart Rate in Age-Matched Long-Evans and
Brattleboro Rats
Rats
LE
DI
MAP
HR
MAP
HR
15-19
0.059±0.005
0.079±0.007
0.077±0.005*
0.099±0.006t
20-24
0.069±0.002
0.092±0.004
0.078±0.003t
0.111±0.005*
Age (wk)
25-29
0.071 ±0.003
0.099±0.004
0.075+0.003
0.112±0.005*
30-34
0.071 ±0.003
0.116±0.008
0.082±0.003'
0.107±0.004
35 +
0.075+0.003
0.133±0.004
0.084±0.004t
0.128±0.006
Values are mean+SEM. LE, Long-Evans rats; MAP, mean arterial pressure; HR, heart rate; DI, Brattleboro rats.
tp<0.05; *p<0.01 compared with Long-Evans rats.
significant change in mean arterial pressure (101 ±2.9
vs. 100+2.9 mm Hg), heart rate (335±7.2 vs. 333±6.9
beats/min), and the standard deviations of mean
arterial pressure (7.6±0.5 vs. 8.3±0.5 mmHg) and
heart rate (41.1 ±3.4 vs. 38.6±3.2 beats/min) aver-
aged for the 21-hour study period. Thirty minutes
after cessation of the AVP antagonist infusion, the
pressor effect of AVP in a dose of 100 ng/kg
(51.7±1.8 mmHg before AVP antagonist infusion)
was completely inhibited.
Effects of Centrally Administered Arginine
Vasopressin, Desmopressin, or Arginine Vasopressin
Antagonist on Blood Pressure, Heart Rate,
and Their Lability
Intracerebroventricular infusion of ACSF did not
cause any significant change in blood pressure, heart
rate, or their lability throughout the infusion period,
and the time-dependent variations in each parameter
were reproducible between the two experiments of
ACSF infusion.
Because intracerebroventricular infusion of AVP
or AVP analogue induced biphasic or triphasic
responses, a time-sequence analysis was performed.
Intracerebroventricular infusion of AVP to LE rats
caused a gradual increase in mean arterial pressure
that reached a peak 4 hours after the start of the
infusion. The mean arterial pressure remained above
the control level (0 hour) during the 20th hour of the
infusion (Figure 5A, two-way ANOVA, FU]4=72.5,
/><0.0001). In DI rats, an initial rise in mean arterial
pressure that lasted approximately 8 hours (0-9
hour, ^,^49=14.6, /><0.0002) was followed by long-
lasting hypotension (Figure 5B) (10-20 hour,
^1,274=23.9,;?<0.0001). The lability of blood pressure
(standard deviation of blood pressure averaged every
hour) in both strains decreased immediately after the
start of the AVP infusion (Figure 5). This stabilizing
effect on the blood pressure lasted throughout the
infusion in DI rats (FiiX3=40.7, p<0.0001), whereas
lability of blood pressure tended to recover to its
control level in LE rats (Ful4=15.6,/7<0.0001). Intra-
cerebroventricular AVP caused a transient increase
in heart rate in both strains. In LE rats, heart rate
returned to the control level 4-8 hours after the start
of the infusion and then increased again and per-
sisted throughout the remainder of the infusion
(Figure 6A) (FU14=28.8, /?<0.0001). On the other
hand, in DI rats an initial tachycardia (statistically
not significant; 0-5 hour, FU49=3.46, p>0.05) was
followed by a long-lasting bradycardia (Figure 6B)
(6-20 hour, Flr374=151.6,/?<0.0001). Urinary volume
was not affected by intracerebroventricular infusion
of AVP in DI rats (315+29.1 vs. 302±32.5 ml/21
hours). The lability of heart rate in both strains
decreased immediately after the start of the AVP
infusion (LE rats FU14=11.2, /?<0.001; DI rats
^1,503=15.9, /?<0.0001). In both strains, the lability of
heart rate recovered to its control level as the infu-
sion continued.
TABLE 2. Control Values of Blood Pressure, Heart Rate, and Lability of Blood Pressure and Heart Rate
Experiment
DI i.v. AVP (2 pg/kg/min)
DI i.v. AVP (0.1 ng/kg/min)
DI i.v. AVP (0.6 ng/kg/min)
DI i.v. DDAVP (0.2 ng/kg/min)
DI i.c.v. AVP (2 pg/kg/min)
DI i.c.v. DDAVP (2 pg/kg/min)
DI i.c.v. DDAVP (0.2 ng/kg/min)
LE i.c.v. AVP (2 pg/kg/min)
LE i.v. AVP-A (50 ng/kg/min)
LE i.c.v. AVP-A (3.3 ng/kg/min)
n
7
8
7
7
13
6
6
8
7
8
MAP
(mm Hg)
113±7.0
115±6.9
113±3.8
111±9.6
115±4.5
130±4.6
120±3.8
106±3.6
99±3.2
101 ±3.0
HR
(beats/min)
354±8.6
360±10J
364±10.0
380±9.3
364±9.7
387±8.1
370±7.9
336±10.5
326±6.1
359+7.8
SDof MAP
(mm Hg)
8J±0.9
7.4±0.8
6.8±1.0
7.3+0.4
8J±1.1
7.5 ±0.6
6.9±0.7
6.8±0.5
5.6±0.2
6.5 ±0.8
SD of HR
(beats/min)
39.4±3.7
38.2±3.9
37.0±4.0
36.9±3.8
37.3±3.4
39.7±2.5
38.8±3.0
41.6±3.6
30.1 ±2.0
41.7±5.7
MAP, mean arterial pressure; HR, heart rate; SD, standard deviation or lability; DI, Brattleboro rats; i.v.,
intravenous; AVP, arginine vasopressin; DDAVP, desmopressin; i.c.v., intracerebroventricular; LE, Long-Evans rats;
AVP-A, vasopressin antagonist.
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FIGURE 3. Plots showing effects of intravenous arginine vasopressin (AVP) infused at rate of 0.6 ng/kg/min for 21-hour study
period (Panel A, n=7) or intravenous desmopressin (DDAVP) infused at rate of 0.2 ng/kg/min for 21 hours (Tanel B, n=7) on
mean arterial pressure (MAP), heart rate (HR), and standard deviations (SD) of MAP and HR (lability) averaged for 21 hours in
Brattleboro (DI) rats. *p<0.05 compared with control Panel C shows effect of intravenous AVP antagonists infused at rate of 50
ng/kg/min for 21 hours on MAP, HR, and SDs of MAP and HR averaged for 21 hours in Long-Evans (LE) rats (n=7).
Intracerebroventricular desmopressin at a rate of 2
pg/kg/min or 0.2 ng/kg/min did not affect mean
arterial pressure, heart rate, or their lability in DI
rats. These doses of intracerebroventricular desmo-
pressin significantly decreased the urinary volume
from 280±27 to 220±19 ml/21 hr or 318±32 to 48±8
ml/21 hr, respectively.
Intracerebroventricular infusion of the AVP
antagonist at a rate of 3.3 pg/kg/min in LE rats
produced transient pressor and tachycardiac actions
(not significant) with stabilization of heart rate
(*i.306=ll-l> p<0.001) during the first few hours.
However, it did not affect the lability of blood
pressure (Figure 7).
Discussion
The present results demonstrate that mean arterial
pressure in DI rats is higher than that in LE rats. This
is in contrast to the results of other workers.17-19
However, in these earlier studies arterial blood pres-
sure was measured in anesthetized rats, in conscious
animals under some degree of stress,17-19 or was
monitored for only a short period.9-17 In contrast to
the blood pressure difference observed in the present
study, there was very little difference in heart rate
between the twostrains of rats. However, lability of
blood pressure and heart rate, which is expressed as
the standard deviations of mean arterial pressure and
heart rate averaged for the 21-hour study period, was
clearly higher in DI than in LE rats.
DI rats have hereditary hypothalamic diabetes
insipidus20 with associated polyuria and polydipsia. It
may be possible that incessant thirst and drinking
may raise blood pressure and induce a high lability of
blood pressure and heart rate in DI rats. This is
unlikely, however, in view of the finding that desmo-
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FIGURE 4. Line graphs showing effect of
intravenous infusion of arginine vasopressin
(AVP) at rate of 0.6 ng/kg/min for 21 hours on
mean arterial pressure (MAP) (Panel A), heart
rate (HR) (Panel B) and standard deviations
(SD) of MAP and HR (lability) averaged every
hour in Brattleboro (DI) rats. 9, Represent
results of time control experiment obtained dur-
ing intravenous infusion of physiological saline.
O, Represent effects of intravenous AVP.
*p<0.05 against control (0 hour) by Duncan's
multiple range test
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FIGURE 5. Line graphs showing effect of
intracerebroventricular infusion of arginine
vasopressin (AVP) at rate of 2 pg/kg/min for
21-hour study period on mean arterial pressure
(MAP) and its standard deviation (SD) aver-
aged every hour in Long-Evans (LE) rats (Pan-
el A) and Brattleboro (DI) rats (Panel B). • ,
Represent results of time control experiment
obtained during intracerebroventricular infu-
sion of artificial cerebrospinal fluid. O, Repre-
sent effect of intracerebroventricular AVP.
*p<0.05 compared with control (0 hour) by
Duncan's multiple range test.
pressin, which completely inhibited polyuria, did not
affect the higher blood pressure and the greater
lability of blood pressure and heart rate in DI rats.
AVP is one of the most potent vasoconstrictor
agents known1 and also increases body fluid volume
by its antidiuretic action on the kidney. In view of
these physiological effects, the absence of the actions
of AVP on the peripheral circulation of DI rats might
be expected to result in hypotension rather than
hypertension. It has been shown, however, that the
vasoconstrictor action of vasopressin works as a small
part of an integrated neurohormonal blood pressure
regulation system, which includes the sympathetic
nervous system, renin-angiotensin system, and many
other regulators.21 When one system is removed, its
influence can be partially and sometimes completely
compensated by increased activity in the remaining
systems.22'23 Thus, the deficiency of circulating AVP
in DI rats may not necessarily result in hypotension,
but the relatively higher blood pressure levels
observed in DI rats are not easily explained. Several
possible mechanisms may be postulated. It is known
that the activity of the renin-angiotensin system is
enhanced in DI rats, possibly as a means of compen-
sating for the absence of AVP.24 However, under the
same experimental conditions as applied in the pres-
ent study, Hiwatari et al23 demonstrated that, after
total autonomic blockade, blood pressure in DI rats
was lower than that in LE rats, and the renin-
angiotensin system was activated more by autonomic
blockade in the former. Therefore, higher blood
pressure in DI rats may not be attributable to
enhanced activity of the renin-angiotensin system.
It has been shown that AVP has a specific and
direct effect on modulating baroreceptor reflexes.6-12
Earner studies have demonstrated that DI rats have
a depressed baroreceptor reflex function that can be
corrected by intravenous infusion of AVP or
desmopressin.9 The depressed baroreceptor reflex
function in DI rats is also supported by the fact that
the lability of blood pressure and heart rate in DI rats
was greater than that in LE rats, and the exaggerated
lability was diminished by intravenous or intracere-
broventricular AVP. This effect of intracerebroven-
#T1m« control
v AVP 2pfAf/min
rU(n-U)
FIGURE 6. Line graphs showing effect of
intracerebroventricular infusion of arginine
vasopressin (AVP) at a rate of 2 pg/kg/min for
21-hour study period on heart rate (HR) and its
standard deviation (SD) averaged every hour in
Long-Evans (LE) rats (Panel A) and Brattle-
boro (DI) rats (Panel B). • , Represent results
of time control experiment obtained during
intracerebroventricular infusion of artificial
cerebrospinal fluid. O, Represent effect of intra-
cerebroventricular AVP. *p<0.05 compared
with control (0 hour) by Duncan's multiple
range test
20
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FIGURE 7. Zinc graphs showing effect of
intracerebroventricular infusion of the arginine
vasopressin (AVP) antagonist A(CH2)s
Tyr(Me)-AVP at rate of 3.3 pglkglmin for the
21-hour study period on mean arterial pressure
(MAP), heart rate (HR), and standard devia-
tions (SD) of MAP and HR averaged every
hour in Long-Evans (LE) rats. • , Represent
result of time control experiment obtained dur-
ing intracerebroventricular infusion of artificial
cerebrospinal fluid O, Represent effect of intra-
cerebroventricular AVP antagonist. *p<0.05
against control (0 hour) by Duncan's multiple
range test.
tricular AVP could not be explained by its peripheral
action after leakage from the cerebral ventricles; the
same amount of intravenous AVP (2 pg/kg/min) did
not modulate the lability of blood pressure and heart
rate. If we hypothesize that the depressed barorecep-
tor reflex function in DI rats results in a higher level
of blood pressure, the question arises as to why
intravenous AVP did not induce hypotension
through its activating effect on the baroreceptor
reflexes. Our observation was that neither a suffi-
ciently subpressor dose of intravenous AVP (0.1
ng/kg/min) nor a higher dose (0.6 ng/kg/min) caused
any change in blood pressure. Thus, it is unlikely that
the depressor effect produced by activating barore-
ceptor reflex is counterbalanced by the pressor effect
of exogenous AVP. The present study also does not
clarify the reason why intravenous desmopressin,
which potentiates baroreceptor reflex sensitivity in
DI rats,9 did not stabilize blood pressure and heart
rate.
Another possibility to explain the relatively higher
blood pressure in DI rats is that this is due to the
deficiency of central AVP. It has been repeatedly
confirmed that there are extensive extrahypothalamic
vasopressinergic axonal projections from the hypo-
thalamic AVP-producing nuclei, the supraoptic
nucleus (SON) and paraventricular nucleus (PVN),
to the brainstem cardiovascular centers.25-26 Williams
and Johnson27 reported that the activity of the sym-
pathetic nervous system in DI rats is elevated, and
they hypothesized that the elevated sympathetic
nerve activity in this strain is mediated by the defi-
ciency of AVP in the central nervous system. Thus, it
is possible that the high blood pressure in DI rats is
mediated by a deficiency of a central vasopressinergic
system by which tonic cardiovascular inhibition is
maintained. The present results may support the
hypothesis that the deficiency of central AVP is
responsible for higher blood pressure and higher
lability of blood pressure and heart rate in DI rats
because intracerebroventricular AVP infusion to DI
rats lacking endogenous AVP induced hypotension
and bradycardia. In addition to these effects, intra-
cerebroventricular AVP also dramatically reduced
the lability of blood pressure and heart rate in both
strains of rats.
In previous studies, centrally administered AVP
has been reported to cause hypertension and tachy-
cardia in rats.28"30 The pressor and tachycardiac
effects of intracerebroventricular AVP reported pre-
viously or observed also in the present study might be
mediated by the midbrain or brainstem cardiovascu-
lar centers because microinjection of AVP to the
nucleus tractus solitarii (NTS) or locus coerulelus
also produced hypertension and tachycardia.31-32
Thus, it is possible to postulate that central AVP acts
as a neurotransmitter or neuromodulator in cardio-
vascular regulatory centers, and may, directly or
indirectly, induce both pressor and depressor effects.
It has been reported that the central administration
of lysine vasopressin to dogs or cats caused decreases
in blood pressure.33-34 Furthermore, Brattstrom et
al35 recently observed the hypotensive and brady-
cardic effects of a picogram range of vasopressin
administered into the NTS of rats. We also observed
that protracted infusion of a small amount of intra-
cerebroventricular AVP induced long-lasting hypo-
tension and bradycardia in stroke-prone SHR,
whereas it induced hypertension and tachycardia in
WKY rats.15 Several authors have reported a
decreased AVP content in brain nuclei of SHR.36-38
It has also been reported that central vasopressiner-
gic neuronal mechanisms contribute to attenuating
the centrally mediated pressor effects of stimulation
of mesencephalic reticular formation.39-40 These find-
ings suggest that central vasopressinergic mechanism
may act, at least partly, as a vasodepressor neuro-
transmitter or neuromodulator. In view of this, it is
possible that the hypotensive and bradycardic effects
of intracerebroventricular AVP in DI rats reported
in the present study as well as in SHR reported
previously15 are mediated by the action of AVP at
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loci where AVP acts tonically to cause cardiovascular
depression. The same hypothesis may explain the
relatively high blood pressure in DI rats, which can
be attributed to the deficiency of cardiovascular
inhibition by central AVP as expected in SHR.15 In
LE rats, endogenous AVP may occupy the region
where exogenous AVP induces cardiovascular
depression in DI rats; additional AVP stimulation
would cause no further decrease in blood pressure
and heart rate. The reason why the heart rate in DI
rats was not higher than that in LE rats warrants
further study.
A final issue worthy of discussion is the dissocia-
tion of the effects of AVP, desmopressin, and AVP
antagonist on cardiovascular parameters. In the pres-
ent study, intravenous or intracerebroventricular
AVP, both Vi vascular and V2 renal receptor agonist,
lowered blood pressure or heart rate and diminished
the lability of blood pressure and heart rate in DI
rats. However, intravenous or intracerebroventricu-
lar desmopressin, which is the preferential V2 renal
receptor agonist,41 did not. Thus, it seems that hyper-
tension or bradycardia and lability of blood pressure
and heart rate are not mediated through a V2 recep-
tor mechanism. Furthermore, the intravenous or
intracerebroventricular V[ receptor antagonist
d(CH2)Tyr(Me)-AVP,16 modulated neither the labil-
ity of blood pressure and heart rate nor basal blood
pressure and heart rate in LE rats. The doses of
intracerebroventricular and intravenous AVP antag-
onist used in the present study (3.3 pg/kg/min and 50
ng/kg/min, respectively) may be enough to block the
effect of endogenous AVP. Certainly intravenous
AVP antagonist was sufficient to abolish the effect of
a huge amount of intravenous AVP administered as
a single bolus. It can be calculated that the AVP
antagonist dose/AVP dose ratio is higher for the
intracerebroventricular (1.7) than the intravenous
route (0.5) of administration. Because blockade was
demonstrated for the intravenous protocol, it could
be argued that, in view of the higher dose ratio, this
dose should be adequate blockade for the intra-
cerebroventricular protocol. Also, because the pres-
sor effect of AVP was still completely inhibited even
after a few hours of infusion of AVP antagonist (the
data are not presented), the half-life of AVP antag-
onist may be extremely longer than that of AVP.
Thus, it is hypothesized that intracerebroventricular
AVP antagonist at a rate of 3.3 pg/kg/min would
attain a CSF concentration level high enough to
block the effect of AVP in CSF. Although it is still
uncertain whether the AVP antagonist can block the
effect of endogenous AVP within the central nervous
system, these results may indicate that the receptor
mechanism that mediates the effects on blood pres-
sure and heart rate is not identical to the classic V,
receptor. It has been reported previously that the
AVP receptor in the central nervous system might
well differ from both V[ and V2 receptors.42-45 Ana-
logues of AVP that do not possess the classic periph-
eral effects of AVP still exhibit central activity.43 In
the present study, intracerebroventricular AVP
antagonist did not change blood pressure, heart rate,
and the lability of blood pressure and heart rate, but
rather stabilized the heart rate in LE rats. It is
possible that the agonistic action of the AVP
antagonist46 or its metabolite may act in the central
nervous system to produce AVP-like effects. These
results, however, warrant a more systematic explora-
tion of the mechanism for the centrally mediated
cardiovascular effect of AVP.
Acknowledgment
Brattleboro and Long-Evans rats raised at Monash
University, Melbourne, Australia, were supplied
from the Institute for Experimental Animals, Tohoku
University. Professor Toshima Nobunaga is respon-
sible for breeding and maintaining these rats.
References
1. Altura BM, Altura BT: Actions of vasopressin, oxytocin, and
synthetic analogs on vascular smooth muscle. Fed Proc 1984;
43:80-86
2. Padfield PL, Brown JJ, Lever AF, Morton JJ, Robertson JIS:
Changes of vasopressin in hypertension: Cause or effect?
Lancet 1976;1:1255-1257
3. Cowley AW Jr, Monos E, Guyton AC: Interaction of vasopres-
sin and the baroreceptor reflex system in the regulation of
arterial blood pressure in the dog. Circ Res 1974;34:505-514
4. Montani J-P, Liard J-F, Schoun J, Mdhring J: Hemodynamic
effects of exogenous and endogenous vasopressin at low
plasma concentrations in conscious dogs. Circ Res 1980;
47:346-355
5. Pullan PT, Johnston CI, Anderson WP, Korner PI: Plasma
vasopressin in blood pressure homeostasis and in experimental
renal hypertension. Am J Physiol 1980;239:H81-H87
6. Berecek KH, Webb RL, Brody MJ: Evidence for a central role
for vasopressin in cardiovascular regulation. Am J Physiol
1983;244:H852-H859
7. Courtice GP, Kwong TE, Lumbers ER, Potter EK: Excitation
of the cardiac vagus by vasopressin in mammals. / Physiol
1984;354:547-556
8. Cowley AW Jr, Merrill D, Osborn J, Barber BJ: Influence of
vasopressin and angiotensin on baroreflexes in the dog. Circ
Res 1984;54:163-172
9. Imai Y, Nolan PL, Johnston CI: Restoration of suppressed
baroreflex sensitivity in rats with hereditary diabetes insipidus
(Brattleboro rats) by arginine-vasopressin and DDAVP. Circ
Res 1983^3:140-149
10. Liard JF, Deriaz O, Tschopp M, Schoun J: Cardiovascular
effects of vasopressin infused into the vertebral circulation of
conscious dogs. Clin Sci 1981;61:345-347
11. Schmid PG, Guo GB, Abboud FM: Different effects of
vasopressin and angiotensin II on baroreflexes. Fed Proc
1985;44:2388-2392
12. Undesser KP, Hasser EM, Haywood JR, Johnson AK, Bishop
VS: Interactions of vasopressin with the area postrema in
arterial baroreflex function in conscious rabbits. Circ Res
1985^6:410-417
13. Ferrario CM, Gildenberg PL, McCubbin JW: Cardiovascular
effects of angiotensin mediated by the central nervous system.
Circ Res 1972;30:257-262
14. Imai Y, Sasaki S, Abe K, Minami N, Sekino H, Yoshinaga K:
Centrally mediated hypotensive and blood pressure stabilizing
effect of vasopressin in Brattleboro rat. / Hypertens 1986;
4:s582-s584
15. Imai Y, Abe K, Sasaki S, Minami N, Nobunaga T, Sekino H,
Yoshinaga K: Hypotensive and bradycardic effects of centrally
administered vasopressin in stroke-prone spontaneously
hypertensive rats. Hypertension 1987;10:346-349
 at TOHOKU UNIVERSITY on September 15, 2011http://hyper.ahajournals.org/Downloaded from 
300 Hypertension Vol 15, No 3, March 1990
16. Sawyer WH, Grzonka Z, Manning M: Neurohypophysial
peptides. Design of tissue-specific agonists and antagonist. Mol
Cell Endoainol 1981;22:117-134
17. Fejes-T6th G, Naray-Fejes-T6th A, Ratge D, Frdlich JC:
Chronic arterial and venous catheterization of conscious,
unrestrained rats. Hypertension 1984;6:926-930
18. Gardiner SM, Bennett T: The control of heart rate in rats with
hereditary hypothalamic diabetes insipidus (Brattleboro
strain). Ann NYAcad Sci 1982;394:363-373
19. Laycock JF, Perm W, Shirley DG, Walter SJ: The role of
vasopressin in blood pressure regulation immediately follow-
ing acute haemorrhage in the rat. / Physiol (Lond) 1979;
296:267-275
20. Valtin H, Schroeder HA; Familial hypothalamic diabetes
insipidus in rats (Brattleboro strain). Am J Physiol 1964;
206:425-430
21. Johnston CI: Vasopressin in circulatory control and hyperten-
sion. J Hypertens 1985^:557-569
22. Gavras H, Hatzinikolaou P, North WG, Bresnahan M, Gavras
I: Interaction of the sympathetic nervous system with vaso-
pressin and renin in the maintenance of blood pressure.
Hypertension 1982;4:4O0-405
23. Hiwatari M, Nolan PL, Johnston CI: The contribution of
vasopressin and angiotensin to the maintenance of blood
pressure after autonomic blockade. Hypertension 1985;
7:547-553
24. Reid IA, Schwartz J, Ben L, Maselli J, Keil LC: Interactions
between vasopressin and the renin-angiotensin system. Prog
Brain Res 1983;60:475-491
25. Buijs RM, Swaab DF, Dogterom J, VanLeeuwen FW: Intra-
and extrahypothalamic vasopressin and oxytocin pathways in
the rats. Cell Tissue Res 1978;186:423-433
26. Sofroniew MV, Schrell U: Evidence for a direct projection
from oxytocin vasopressin neurons in the hypothalamic
paraventricular nucleus to the medulla oblongata: Immuno-
histochemical visualization of both the horseradish peroxidase
transported and the peptide produced by the same neurons.
Neumsci Lea 1981;22:211-217
27. Williams JL Jr, Johnson MD: Sympathetic nervous system and
blood pressure maintenance in the Brattleboro DI rat. Am J
Physiol 1986;250:R770-R775
28. Feuerstein G, Zerbe RL, Faden AI: Central cardiovascular
effects of vasotocin, oxytocin and vasopressin in conscious rats.
J Pharmacol Exp Ther 1984;228:348-353
29. Pittman QJ, Lawrence D, McLean L: Central effects of
arginine vasopressin on blood pressure in rats. Endocrinology
1982;110:1058-1060
30. Zerbe RL, Rutland S, Faden AI, Feuerstein G: Central
cardiovascular effects of mammalian neurohypophyseal pep-
tides in conscious rats. Peptide 1983;4:627-630
31. Berecek KH, Olpe HR, Jones RSG, Hofbauer KG: Microin-
jection of vasopressin into the locus coeruleus of conscious
rats. Am J Physiol 1984;247:H675-H681
32. Matsuguchi H, Sharabi FM, Gordon FJ, Johnson AK: Blood
pressure and heart rate responses to microinjection of vaso-
pressin into the nucleus tractus solitarius region of the rats.
Neumpharmacology 1982^1:687-693
33. Nashold BS, Mannarino E, Wunderlich M: Pressor-depressor
blood pressure responses in the cat after intraventricular
injection of drugs. Nature 1962;193:1297-1298
34. Tran LD, Montastruc J-L, Montastruc P: Effects of lysine-
vasopressin and oxytocin on central cardiovascular control. Br
J Pharmacol 1982;77:69-73
35. Brattstrom A, DeJong W, DeWied D: Vasopressin microin-
jections into the nucleus tractus solitarii decrease heart rate
and blood pressure in anaesthetized rats. / Hypertens 1988;
6{suppl 4):S521-S524
36. MOhring J, Schoun J, Kintz J, McNeill R: Decreased vasopres-
sin content in brain stem of rats with spontaneous hyperten-
sion. Naunyn Schmiedebergs Arch Pharmacol 1980;315:83-84
37. Morris M, Keller M, Sundberg DK: Changes in paraventricu-
lar vasopressin and oxytocin during the development of spon-
taneous hypertension. Hypertension 1983^:476-481
38. Rascher W, Lang RE, Unger T, Ganten D, Gross F: Vaso-
pressin in brain of spontaneously hypertensive rats. Am J
Physiol 1982;242:H496-H499
39. Versteeg CAM, Bohus B, DeJong W: Attenuation by arginine-
and desgh/cinamide-lysine-vasopressin of a centrally evoked
pressor response. J Auton Nerv Syst 1982;6:253-262
40. Versteeg CAM, DeJong W, Bohus B: Arginine'-vaspopressin
inhibits centrally induced pressor responses by involving hip-
pocampal mechanisms. Brain Res 1984;292:317-326
41. Vavra I, Machova A, Holecek V, Cort JH, Zaoral M, Sorm F:
Effect of a synthetic analogue of vasopressin in animals and in
patients with diabetes insipidus. Lancet 1968;l:948-952
42. Antoni FA: Novel ligand specificity of pituitary vasopressin
receptors in the rat. Neuwendocrinology 1984^9:186-188
43. DeWied D: Central actions of neurohypophysial hormones.
Prog Brain Res 1983;60:155-167
44. Knepel W, Homolka L, Vlaskovska M, Nutto D: In vivo
adrenocorricotropin 0-endorphin releasing activity of vaso-
pressin analogues is related neither to pressor nor to antidi-
uretic activity. Endocrinology 1984;114:1797-1804
45. Manning M, Sawyer WH: Design and uses of selective agonis-
tic and antagonistic analogs of the neuropeptides oxytocin and
vasopressin. Trend Neurosci 1984;7:6-9
46. Liard JF, Spadone JC: Hemodynamic effects of antagonists of
the vasoconstrictor action of vasopressin in conscious dogs. /
Cardiovasc Pharmacol 1984;6:713-719
KEY WORDS • arginine vasopressin • blood pressure • central
nervous system • heart rate • Brattleboro rat • Long-Evans rat
 at TOHOKU UNIVERSITY on September 15, 2011http://hyper.ahajournals.org/Downloaded from 
